Randomized trial of the immunogenicity and safety of the hepatitis B vaccine given in an accelerated schedule coadministered with the human papillomavirus type 16/18 AS04-adjuvanted cervical cancer vaccine

Clinical and Vaccine Immunology

Volumn 18, Issue 9, 2011, Pages 1510-1518

  Leroux Roels, Geert ^a   Haelterman, Edwige ^b   Maes, Cathy ^a   Levy, Jack ^b   De Boever, Fien ^a   Licini, Laurent ^b   David, Marie Pierre ^c   Dobbelaere, Kurt ^c   Descamps, Dominique ^c  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Centre Hospitalier Universitaire de Tivoli   (Belgium)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; CANCER IMMUNIZATION; CLINICAL PROTOCOL; COMBINATION CHEMOTHERAPY; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; CYSTITIS; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE RASH; INJECTION SITE SWELLING; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MONOTHERAPY; MYALGIA; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SKIN ALLERGY; SORE THROAT; URTICARIA; UTERINE CERVIX CANCER; VACCINATION REACTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ALUMINUM HYDROXIDE; ANTIBODIES, VIRAL; CANCER VACCINES; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; LIPID A; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 80052501750     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00539-10     Document Type: Article

References (36)

1. Bock, H. L., et al. 1995. Accelerated schedule for hepatitis B immunization. J. Travel Med. 2:213-217.
2. Bosch, F. X., et al. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl. 10):K1-K16.
3. Brown, D. R., et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J. Infect. Dis. 199:926-935.
4. Cambron, P., J.-M. Jacquet, B. Hoet, and M. Lievens. 2009. Development and technical and clinical validation of a quantitative enzyme-linked immunosorbent assay for the detection of human antibodies to hepatitis B surface antigen in recipients of recombinant hepatitis B virus vaccine. Clin. Vaccine Immunol. 16:1236-1246.
5. Descamps, D., et al. 2009. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials. Hum. Vaccin. 5:332-340.
6. Einstein, M. H., et al. 2009. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5:705-719.
7. Ferlay, J., et al. (ed.) 2008. Globocan 2008: cancer incidence and mortality worldwide. IARC CancerBase no. 10. International Agency for Research on Cancer, Lyon, France.
8. FUTURE II Study Group. 2007. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356:1915-1927.
9. Garcia-Sicilia, J., et al. 2010. Immunogenicity and safety of human papillomavirus- 16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J. Adolesc. Health 46:142-151.
10. Garçon, N., P. Chomez, and M. Van Mechelen. 2007. GlaxoSmithKline adjuvant systems in vaccines: Concepts, achievements and perspectives. Expert Rev. Vaccines 6:723-739. (Pubitemid 47607848)
11. Giannini, S. L., et al. 2006. Enhanced humoral and memory B cell immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24:5937-5949. (Pubitemid 44080367)
12. GlaxoSmithKline Vaccine HPV-007 Study Group. 2009. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374:1975-1985.
13. Harper, D. M., et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364:1757-1765. (Pubitemid 39488060)
14. Hess, G., V. Hingst, J. Cseke, H. L. Bock, and R. Clemens. 1992. Influence of vaccination schedules and host factors on antibody response following hepatitis B vaccination. Eur. J. Clin. Microbiol. Infect. Dis. 11:334-340.
15. Jack, A. D., A. J. Hall, N. Maine, M. Mendy, and H. C. Whittle. 1999. What level of hepatitis B antibody is protective? J. Infect. Dis. 179:489-492. (Pubitemid 29086654)
16. Keating, G. M., and S. Noble. 2003. Recombinant hepatitis B vaccine (Engerix-B): A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63:1021-1051. (Pubitemid 36575466)
17. Marsano, L. S., et al. 1996. Comparison of a rapid hepatitis B immunization schedule to the standard schedule for adults. Am. J. Gastroenterol. 91:111-115. (Pubitemid 26026048)
18. Mast, E. E., et al. 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: Immunization of infants, children, and adolescents. MMWR Recommend. Rep. 54(RR16):1-23.
19. Mast, E. E., et al. 2006. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: Immunization of infants, children, and adolescents. MMWR Recommend. Rep. 55(RR16):1-31.
20. Muñoz, N., et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527. (Pubitemid 36159887)
21. Muñoz, N., et al. 2010. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J. Natl. Cancer Inst. 102:325-339.
22. Paavonen, J., et al. 2007. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170. (Pubitemid 46977438)
23. Paavonen, J., et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
24. Pedersen, C., et al. 2009. Co-administration of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine with hepatitis A/B vaccine in girls aged 9-15 years, abstr. 099. Abstr. 6th World Congress of World Society for Pediatric Infectious Diseases, Buenos Aires, Argentina, 18 to 22 November, 2009.
25. Poovorawan, Y., et al. 2011. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. J. Viral Hepat. 18:363-375.
26. Rustgi, V. K., C. J. Schleupner, and D. S. Krause. 1995. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults. Vaccine 13:1665-1668. (Pubitemid 26013308)
27. Schwarz, T. F., et al. 2009. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 22:581-587.
28. Van Herck, K., E. Leuridan, and P. Van Damme. 2007. Schedules for hepatitis B vaccination of risk groups: Balancing immunogenicity and compliance. Sex. Transm. Infect. 83:426-432. (Pubitemid 350063839)
29. Verstraeten, T., et al. 2008. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26:6630-6638.
30. Vryheid, R. E., M. A. Kane, N. Muller, G. C. Schatz, and S. Bezabeh. 2000. Infant and adolescent hepatitis B immunization up to 1999: A global overview. Vaccine 19:1026-1037. (Pubitemid 32008267)
31. Wheeler, C. M., et al. 2008. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26:686-696.
32. Wheeler, C. M., et al. 2009. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J. Infect. Dis. 199:936-944.
33. World Health Organization. 2009. Hepatitis B vaccines. WHO Position Paper. Wkly. Epidemiol. Rec. 84:405-420.
34. Wright, T. C., et al. 2008. Age considerations when vaccinating against HPV. Gynecol. Oncol. 109:S40-S47.
35. Zanetti, A. R., P. Van Damme, and D. Shouval. 2008. The global impact of vaccination against hepatitis B: A historical overview. Vaccine 26:6266-6273.
36. zur Hausen, H. 1996. Papillomavirus infections - A major cause of human cancers. Biochim. Biophys. Acta 1288:F55-F78.